DRG Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s NSCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with NSCLC per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with NSCLC per year?
  • How will improvements in survival change the number of first-line drug-treatment opportunities for NSCLC?
  • How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for NSCLC?
  • Of all people diagnosed with NSCLC, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following NSCLC subpopulations:

  • Diagnosed incident cases: adenocarcinoma by ALK translocation status.
  • Diagnosed incident cases: adenocarcinoma by EGFR translocation status.
  • Diagnosed incident cases: adenocarcinoma by KRAS mutation status.
  • Diagnosed incident cases: adenocarcinoma by stage and resection status.
  • Diagnosed incident cases: NSCLC by ALK translocation status.
  • Diagnosed incident cases: NSCLC by EGFR mutation status.
  • Diagnosed incident cases: NSCLC by KRAS mutation status.
  • Diagnosed incident cases: squamous NSCLCby stage and resection status.
  • Diagnosed incident cases:NSCLCunverified by stage at diagnosis.

Note: Coverage may vary by country.

Table of contents

  • Non-Small-Cell Lung Cancer - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
        • Overview
          • Incident Cases of Non-Small Cell Lung Cancer per 100,000 People of All Ages in 2020 and 2030
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Non-Small Cell Lung Cancer over the Next 10 Years
          • Analysis of the Incident Cases of Non-Small Cell Lung Cancer in 2020 by Stage
      • Epidemiology data
      • Methods
        • Newly Diagnosed Incidence
        • Stage Distribution
        • Mutation Status
        • Diagnosed Prevalence
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-treated Populations
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of NSCLC
          • Studies Excluded in the Analysis of NSCLC
        • Risk/Protective Factors
          • Risk/Protective Factors for NSCLC
        • Bibliography
        • Glossary

    Author(s): Nishant Kumar, M.P.H.

    Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


    Related Reports

    Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

    Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.

    View Details

    Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020

    Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...

    View Details

    Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)

    Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

    View Details

    Non-Small-Cell Lung Cancer - Epidemiology - Epidemiology Dashboard

    DRG Epidemiology’s coverage of non-small cell lung cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

    View Details